Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment.

Published
18 hours ago
From
Hep C Coalition
Gilead’s Gaffe Leads Drugmakers to Pledge More Openness on Price

Drugmakers worried about a backlash over soaring drug prices are increasingly talking with insurers ahead of time about paying for new therapies that could cost six figures a year.

Published
18 hours ago
From
Bloomberg
Egypt opens first factory for locally produced Sovaldi

Egypt's health minister said Hepatitis C is "one of the most dangerous threats to Egypt", on Sunday during the opening ceremony of a factory for the local production of Hepatitis C medication Sovaldi.

Published
18 hours ago
From
News Egypt
Gilead first-quarter profit doubles on strong hepatitis C drug sales

Gilead Sciences Inc on Thursday said its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs, as it topped Wall Street estimates. Gilead signaled that, with its hepatitis C franchise established, it is a good time for the company to consider business development opportunities. "We want to stick very closely to therapeutic areas we are in today," Gilead Chief Operating Officer John Milligan said on a conference call.

Published
18 hours ago
From
Reuters
Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Merck has previously stated that it will seek approval for the grazoprevir/elbasvir combination pill in the middle of the year. If approved by the end of the year or in early 2016 -- and there's probably little risk the therapy won't be approved -- Merck's dilemma will be finding a way to grab market share for a new hepatitis C therapy without any clinical or convenience advantages over the existing competition.

Published
09 April 2015
From
The Street
ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations

Through Positive Action, ViiV Healthcare has committed to invest £2 million per year to encourage MSM and transgender community-led interventions to reduce stigma and discrimination based on sexual orientation, gender identity/expression and/or HIV status. The first phase of the new programme will cover a period of two years.

Published
31 March 2015
From
Viiv Healthcare press release
Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race

Bristol-Myers Squibb took an intriguing approach to developing its hepatitis C drug, daclatasvir. Rather than focus its trials on the United States, the globe's biggest market for spending on medicine, it concentrated trials on Japan. That move allowed daclatasvir to carve out an early lead in Japan, but it also left investors wondering what the company's strategy for the drug in the United States would be -- particularly after the FDA balked at an initial application to approve the drug last fall. This week, Bristol-Myers shed some light on its strategy by announcing that it's resubmitting daclatasvir for approval in the U.S. as an adjunct treatment to be used alongside Gilead Sciences' (NASDAQ: GILD ) top-selling HCV drug Sovaldi in genotype 3 patients.

Published
18 March 2015
From
Motley Fool
Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

Sangamo's purportedly ground-breaking results in HIV with SB-728 do not stand up under close examination. SB-728 has not shown any indication that it can provide a "functional cure" for HIV, does not compare well to today's standard of care, and cannot find a partner. Sangamo refuses to conduct studies that rigorously assess whether their drugs work. This includes the inclusion of a control arm so assiduously avoided by Sangamo's management.

Published
10 March 2015
From
Seeking Alpha
Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

Based on the prescription data released by Symphony Health, the latest Bloomberg Intelligence (BI) analysis suggests that 95% of hepatitis C patients in the US are being administered with Gilead’s drugs, Harvoni and Sovaldi. On the other hand, AbbVie’s competing drug, Viekira Pak is only covering the remaining 4%.

Published
10 March 2015
From
Bidness
$10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.

Published
09 March 2015
From
Bloomberg
← First12345...76Next →

Filter by country